作为抗阿尔茨海默氏症药物的他克林修饰席夫碱的绿色合成:通过室内和体外分析验证的有效策略

IF 3.8 Q2 CHEMISTRY, PHYSICAL
Presenjit , Shubhra Chaturvedi , Akanksha , Deepika Sharma , Ritika Chaudhary , Prachi Verma , Ankita Singh , Kaman Singh
{"title":"作为抗阿尔茨海默氏症药物的他克林修饰席夫碱的绿色合成:通过室内和体外分析验证的有效策略","authors":"Presenjit ,&nbsp;Shubhra Chaturvedi ,&nbsp;Akanksha ,&nbsp;Deepika Sharma ,&nbsp;Ritika Chaudhary ,&nbsp;Prachi Verma ,&nbsp;Ankita Singh ,&nbsp;Kaman Singh","doi":"10.1016/j.chphi.2024.100759","DOIUrl":null,"url":null,"abstract":"<div><div>A variety of Tacrine-modified Schiff base analogues were developed via solvent free (green) method and structurally elucidated using 1H<img>NMR, FTIR and UV–Vis analysis. High product yield was obtained from the synthesised molecules, which were produced efficiently at room temperature without the need of a solvent. The developed molecules were subsequently assessed for their potential to inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). These molecules revealed effective inhibition of AChE and BChE enzymes with IC<sub>50</sub> values varying from 0.1 ± 0.02 to 0.3 ± 0.03 μM and 0.065 ± 0.01 to 0.3 ± 0.03 μM respectively. Compared to the standard Tacrine which has IC<sub>50</sub> values of 0.35 ± 0.02 μM for AChE and 0.1 ± 0.01 μM for BChE. Notably, compound 3f showed strong inhibition among others for both the enzymes. The structure–activity relationship of derivatives synthesized were verified and established through molecular docking studies. Theoretical ADME studies also predicted excellent drug-likeness for all the synthesized molecules. Antioxidant activities were also assessed because elevated oxidative stress levels are linked with cognitive loss in Alzheimer's disease (AD). These findings suggest that the lead compound is potentially an effective inhibitor for the therapeutic management of AD.</div></div>","PeriodicalId":9758,"journal":{"name":"Chemical Physics Impact","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Green synthesis of Tacrine modified Schiff bases as anti-Alzheimer Agents: An effective strategy validated through in-silico and in-vitro analysis\",\"authors\":\"Presenjit ,&nbsp;Shubhra Chaturvedi ,&nbsp;Akanksha ,&nbsp;Deepika Sharma ,&nbsp;Ritika Chaudhary ,&nbsp;Prachi Verma ,&nbsp;Ankita Singh ,&nbsp;Kaman Singh\",\"doi\":\"10.1016/j.chphi.2024.100759\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>A variety of Tacrine-modified Schiff base analogues were developed via solvent free (green) method and structurally elucidated using 1H<img>NMR, FTIR and UV–Vis analysis. High product yield was obtained from the synthesised molecules, which were produced efficiently at room temperature without the need of a solvent. The developed molecules were subsequently assessed for their potential to inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). These molecules revealed effective inhibition of AChE and BChE enzymes with IC<sub>50</sub> values varying from 0.1 ± 0.02 to 0.3 ± 0.03 μM and 0.065 ± 0.01 to 0.3 ± 0.03 μM respectively. Compared to the standard Tacrine which has IC<sub>50</sub> values of 0.35 ± 0.02 μM for AChE and 0.1 ± 0.01 μM for BChE. Notably, compound 3f showed strong inhibition among others for both the enzymes. The structure–activity relationship of derivatives synthesized were verified and established through molecular docking studies. Theoretical ADME studies also predicted excellent drug-likeness for all the synthesized molecules. Antioxidant activities were also assessed because elevated oxidative stress levels are linked with cognitive loss in Alzheimer's disease (AD). These findings suggest that the lead compound is potentially an effective inhibitor for the therapeutic management of AD.</div></div>\",\"PeriodicalId\":9758,\"journal\":{\"name\":\"Chemical Physics Impact\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chemical Physics Impact\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667022424003037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, PHYSICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical Physics Impact","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667022424003037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}
引用次数: 0

摘要

通过无溶剂(绿色)方法开发了多种他克林修饰的希夫碱类似物,并利用 1HNMR、傅立叶变换红外光谱和紫外可见光谱分析对其结构进行了阐明。合成的分子在室温下无需溶剂即可高效生产,产品收率高。随后评估了所开发分子抑制乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BChE)的潜力。这些分子能有效抑制乙酰胆碱酯酶(AChE)和丁酰胆碱酯酶(BChE),其 IC50 值分别为 0.1 ± 0.02 至 0.3 ± 0.03 μM 和 0.065 ± 0.01 至 0.3 ± 0.03 μM。相比之下,标准药物他克林对 AChE 的 IC50 值为 0.35 ± 0.02 μM,对 BChE 的 IC50 值为 0.1 ± 0.01 μM。值得注意的是,化合物 3f 对这两种酶都有很强的抑制作用。通过分子对接研究,验证并确立了所合成衍生物的结构-活性关系。理论 ADME 研究也预测所有合成的分子都具有极佳的药物相似性。由于氧化应激水平升高与阿尔茨海默病(AD)的认知能力下降有关,因此还对其抗氧化活性进行了评估。这些研究结果表明,该先导化合物可能是治疗阿尔茨海默病的有效抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Green synthesis of Tacrine modified Schiff bases as anti-Alzheimer Agents: An effective strategy validated through in-silico and in-vitro analysis

Green synthesis of Tacrine modified Schiff bases as anti-Alzheimer Agents: An effective strategy validated through in-silico and in-vitro analysis
A variety of Tacrine-modified Schiff base analogues were developed via solvent free (green) method and structurally elucidated using 1HNMR, FTIR and UV–Vis analysis. High product yield was obtained from the synthesised molecules, which were produced efficiently at room temperature without the need of a solvent. The developed molecules were subsequently assessed for their potential to inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). These molecules revealed effective inhibition of AChE and BChE enzymes with IC50 values varying from 0.1 ± 0.02 to 0.3 ± 0.03 μM and 0.065 ± 0.01 to 0.3 ± 0.03 μM respectively. Compared to the standard Tacrine which has IC50 values of 0.35 ± 0.02 μM for AChE and 0.1 ± 0.01 μM for BChE. Notably, compound 3f showed strong inhibition among others for both the enzymes. The structure–activity relationship of derivatives synthesized were verified and established through molecular docking studies. Theoretical ADME studies also predicted excellent drug-likeness for all the synthesized molecules. Antioxidant activities were also assessed because elevated oxidative stress levels are linked with cognitive loss in Alzheimer's disease (AD). These findings suggest that the lead compound is potentially an effective inhibitor for the therapeutic management of AD.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Chemical Physics Impact
Chemical Physics Impact Materials Science-Materials Science (miscellaneous)
CiteScore
2.60
自引率
0.00%
发文量
65
审稿时长
46 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信